← board
PCYN
distress 0/10 · well-funded / low risk$0.26+4%today-7% from 52w high
Revenue
pre-revenue
Liquidity
$0M
Runway
—
Shares 1y
-90%
Price & events
+114.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
+4.0%
1D
+52.9%
1W
+29.4%
1M
-7.1%
3M
+114.9%
6M
+36.8%
1Y
+24.7%
2Y
-38.1%
5Y
-67.5%
All
Overview
- Market Cap
- $2.11M
- Volume
- 8.97K
- 52 Week Range
- $0.10 – $0.28
- Total Shares
- 8.12M
- Float Shares
- 4.29M
- % Held by Insiders
- 64.47%
- % Held by Institutions
- 0.00%
- RVOL
- 3.85x
- Beta
- 60491.46
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 1
- 2024-11-08withdrawalVoluntarily filed Form 15 to deregister common stock; expects effective 90 days after filing.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 8,120,388 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.